Sign in

Christian Ryom

former Head of Equity Research at Danske Bank

Christian Ryom is a former Head of Equity Research at Danske Bank, specializing in Scandinavian healthcare companies with direct coverage of firms such as Coloplast, Ambu, Demant, and GN. While at Danske Bank, he maintained coverage on two significant stocks with a measured success rate of 50% and a rating of 1.73 stars on analyst performance platforms. Ryom's career at Danske Bank focused on equity research, and he recently transitioned to become Head of Investor Relations at Leo Pharma in October 2024. His professional background emphasizes deep sector expertise and cross-company analysis, though industry records do not publicly list further securities licenses or specific professional credentials.

Christian Ryom's questions to GNNDY leadership

Question · Q1 2024

Questioned the strong Enterprise gross margin for any exceptional items, the size of the pension provision reversal in Hearing, and how to reconcile the flat growth in Gaming & Consumer with the reported mid-single-digit growth in its core categories.

Answer

The Enterprise gross margin strength was not due to one-offs but a combination of good product mix, cost normalization, and synergies. The pension provision reversal in Hearing was about 2% of the division's top line. The flat result in Gaming & Consumer is because the growth in core categories (SteelSeries, true wireless) was offset by declines in non-strategic products and the BlueParrott range.

Ask follow-up questions

Question · Q3 2023

Inquired about the timeline for the end of gross margin dilution from promotional activity at SteelSeries and whether the announced One-GN synergies represent the full potential or if more could be identified later.

Answer

The gross margin impact from promotions is expected to continue in Q4 due to planned inventory depletion, with the situation for 2024 to be addressed later. The currently announced synergy plan is what the company is committing to as a realistic and ambitious target for the near term, though they are always looking for more optimization opportunities.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts